{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:38:08Z","timestamp":1762004288661,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Austrian Ministry of Science and Research","award":["GZ 200.156\/2-VI\/1a\/2006"],"award-info":[{"award-number":["GZ 200.156\/2-VI\/1a\/2006"]}]},{"name":"Austrian Research Society"},{"name":"Genzyme Corp"},{"name":"Genzyme Corp"},{"name":"Shire Human Genetic Therapies"},{"name":"Genzyme Corp"},{"name":"Shire Human Genetic Therapies"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1053\/j.ajkd.2010.10.046","type":"journal-article","created":{"date-parts":[[2010,12,25]],"date-time":"2010-12-25T05:24:09Z","timestamp":1293254649000},"page":"673-681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Urinary Total Globotriaosylceramide and Isoforms to Identify Women With Fabry Disease: A Diagnostic Test Study"],"prefix":"10.1053","volume":"57","author":[{"given":"Eduard","family":"Paschke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenter","family":"Fauler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heimo","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Schlagenhauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Plecko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Erwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Breunig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Urban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bojan","family":"Vujkovac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kotanko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2010.10.046_bib1","first-page":"3733","article-title":"\u03b1-Galactosidase deficiency: Fabry disease","volume":"Vol 3","author":"Desnick","year":"2001"},{"issue":"3","key":"10.1053\/j.ajkd.2010.10.046_bib2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201drenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2010.10.046_bib3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2010.10.046_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.ajkd.2010.10.046_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1053\/j.ajkd.2010.10.046_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","article-title":"Screening for Fabry disease in high risk populations: a systematic review","volume":"47","author":"Linthorst","year":"2010","journal-title":"J Med Genet"},{"issue":"7","key":"10.1053\/j.ajkd.2010.10.046_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra","year":"2001","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2010.10.046_bib8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"issue":"3","key":"10.1053\/j.ajkd.2010.10.046_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"21","key":"10.1053\/j.ajkd.2010.10.046_bib10","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"issue":"6","key":"10.1053\/j.ajkd.2010.10.046_bib11","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ajkd.2010.10.046_bib12","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"10.1053\/j.ajkd.2010.10.046_bib13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"9706","key":"10.1053\/j.ajkd.2010.10.046_bib14","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1053\/j.ajkd.2010.10.046_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","article-title":"Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study","volume":"26","author":"Baehner","year":"2003","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2010.10.046_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","article-title":"A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease","volume":"11","author":"Whybra","year":"2009","journal-title":"Genet Med"},{"issue":"3","key":"10.1053\/j.ajkd.2010.10.046_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.20144","article-title":"Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography","volume":"25","author":"Shabbeer","year":"2005","journal-title":"Hum Mutat"},{"issue":"9499","key":"10.1053\/j.ajkd.2010.10.046_bib18","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"10.1053\/j.ajkd.2010.10.046_bib19","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1212\/WNL.32.10.1139","article-title":"Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"issue":"2","key":"10.1053\/j.ajkd.2010.10.046_bib20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2215\/CJN.06090809","article-title":"Biomarkers of Fabry disease nephropathy","volume":"5","author":"Schiffmann","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2010.10.046_bib21","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1053\/j.ajkd.2010.10.046_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1053\/j.ajkd.2010.10.046_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","article-title":"Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease","volume":"28","author":"Mills","year":"2005","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2010.10.046_bib24","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1373\/clinchem.2004.041418","article-title":"Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes","volume":"51","author":"Fuller","year":"2005","journal-title":"Clin Chem"},{"issue":"1","key":"10.1053\/j.ajkd.2010.10.046_bib25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2010.10.046_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease\u2014role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2010.10.046_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2004.02.032","article-title":"Globotriaosylceramide isoform profiles in human plasma by liquid chromatography-tandem mass spectrometry","volume":"805","author":"Nelson","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"6","key":"10.1053\/j.ajkd.2010.10.046_bib28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1139\/o81-057","article-title":"The glycosphingolipids of human plasma lipoproteins","volume":"59","author":"Clarke","year":"1981","journal-title":"Can J Biochem"},{"issue":"7-8","key":"10.1053\/j.ajkd.2010.10.046_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF03040321","article-title":"Anderson-Fabry disease in Austria","volume":"115","author":"Lorenz","year":"2003","journal-title":"Wien Klin Wochenschr"},{"issue":"8","key":"10.1053\/j.ajkd.2010.10.046_bib30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1023\/A:1022833332162","article-title":"A novel 6 bp insertion in exon 7 associated with an unusual phenotype in a family with Fabry disease","volume":"25","author":"Kroepfl","year":"2002","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2010.10.046_bib31","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"issue":"8","key":"10.1053\/j.ajkd.2010.10.046_bib32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.ejhg.5201184","article-title":"Remarkable variability in renal disease in a large Slovenian family with Fabry disease","volume":"12","author":"Verovnik","year":"2004","journal-title":"Eur J Hum Genet"},{"issue":"447","key":"10.1053\/j.ajkd.2010.10.046_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr Suppl"},{"issue":"4","key":"10.1053\/j.ajkd.2010.10.046_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/187152506778520718","article-title":"The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature","volume":"4","author":"Bekri","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"6","key":"10.1053\/j.ajkd.2010.10.046_bib35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1053\/j.ajkd.2010.10.046_bib36","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/rcm.1948","article-title":"Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard","volume":"19","author":"Fauler","year":"2005","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"5","key":"10.1053\/j.ajkd.2010.10.046_bib37","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","article-title":"Results of a nationwide screening for Anderson-Fabry disease among dialysis patients","volume":"15","author":"Kotanko","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2010.10.046_bib38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/ki.2009.171","article-title":"Diagnostic methods 2: receiver operating characteristic (ROC) curves","volume":"76","author":"Tripepi","year":"2009","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2010.10.046_bib39","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: a review of current management strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"QJM"},{"key":"10.1053\/j.ajkd.2010.10.046_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2350-11-19","article-title":"Frequency of Fabry disease in male and female haemodialysis patients in Spain","volume":"11","author":"Gaspar","year":"2010","journal-title":"BMC Med Genet"},{"key":"10.1053\/j.ajkd.2010.10.046_bib41","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma blobotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1053\/j.ajkd.2010.10.046_bib42","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1093\/ndt\/gfq108","article-title":"The value of estimated GFR in comparison to measured GFR for the assessment of renal function in adult patients with Fabry disease","volume":"25","author":"Rombach","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2010.10.046_bib43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ymgme.2009.04.009","article-title":"Fabry disease urinary globotriaosylceramide\/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months","volume":"97","author":"Barr","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1053\/j.ajkd.2010.10.046_bib44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0444-3","article-title":"Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease","volume":"30","author":"Auray-Blais","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2010.10.046_bib45","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","article-title":"Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry","volume":"85","author":"Kitagawa","year":"2005","journal-title":"Mol Genet Metab"},{"key":"10.1053\/j.ajkd.2010.10.046_bib46","unstructured":"Kuchar L HJ, Ledvinova J. Changed Gb3Cer isoform pattern in urine: biochemical marker of FD disease useful in monitoring of enzyme replacement therapy. 17th ESGLD Workshop 2009, Bad Honnef, Germany, September 10-13, 2009."}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638610015660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638610015660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:57:04Z","timestamp":1759456624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638610015660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0272638610015660"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2010.10.046","relation":{},"ISSN":["0272-6386"],"issn-type":[{"type":"print","value":"0272-6386"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary Total Globotriaosylceramide and Isoforms to Identify Women With Fabry Disease: A Diagnostic Test Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2010.10.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}